

In response to the February 7, 2001 Office Action, please amend the subject application as follows:

In the Claims:

Please replace present claim 11 with the following claim 11. Submitted herewith as Appendix A on a separate sheet according to the provisions of 37 CFR 1.21(b)(1)(iii) is a version of the previous claims 11 marked-up to show all the changes relative to the replacement claim below:

CLEAN COPY - ENTER:

B 1
11. (Amended) A dual-function vaccine which comprises a fusion protein according to claim 1, a vector according to claim 7, or a transformed cell according to claim 10, in an amount effective to I) inhibit the activity of the peptide from which portion (a) of the fusion protein is derived, and II) to protect against infection by the pathogen from which portion (b) of the fusion protein is derived; and a carrier acceptable for pharmaceutical or veterinary use.